London-based biotech firm Oyster Therapeutics, formerly operating as Kesmalea Therapeutics, has announced the successful closing of a $60 million Series A-2 financing round, marking a significant milestone in the quest to bring targeted protein degradation (TPD) to the field of neurodegeneration. This latest infusion of capital is earmarked for the advancement of the company’s lead therapeutic candidate, a first-of-its-kind oral degrader designed to eliminate pathological tau proteins, which are widely recognized as a primary driver of cognitive decline in Alzheimer’s disease and other tauopathies. The financing highlights a growing industry-wide pivot toward TPD technologies that can overcome the formidable biological barriers of the central nervous system (CNS), specifically the blood-brain barrier (BBB).
The funding round was led by 4BIO Capital and saw participation from a robust syndicate of new and existing investors. Notably, the pharmaceutical giant Eli Lilly and Company, which recently secured FDA approval for its amyloid-targeting antibody Kisunla (donanemab), joined as a new investor, signaling a strategic interest in diversifying its Alzheimer’s portfolio beyond monoclonal antibodies. Other new participants included Actium Group, CE Ventures, and TOHO Ventures, while previous backers Syncona, Oxford Science Enterprises (OSE), Mission BioCapital, and MGB Ventures reaffirmed their support. This latest round brings the total Series A funding for the startup to approximately $93 million, following an initial £25 million ($33 million) raise in 2022.
The Evolution of Targeted Protein Degradation
Targeted protein degradation represents one of the most innovative frontiers in drug discovery. Unlike traditional small molecule inhibitors, which only "block" the function of a protein by binding to its active site, degraders harness the cell’s own waste disposal machinery to physically remove the disease-causing protein entirely. This is achieved through heterobifunctional molecules—often referred to as PROTACs (Proteolysis Targeting Chimeras)—which act as a bridge. One end of the molecule binds to the target protein, while the other recruits an E3 ubiquitin ligase, an enzyme that marks the protein with a "kiss of death" (ubiquitin tags). This tag directs the protein to the proteasome, the cell’s internal recycling center, where it is broken down into harmless amino acids.
While TPD has seen rapid success in oncology, where the first degraders reached the market earlier this year, applying this modality to the brain has remained a "Gordian knot" for researchers. The primary obstacle is the physical size of the molecules. To accommodate two distinct binding heads and a chemical linker, protein degraders are significantly larger than conventional small molecules. This increased molecular weight typically prevents them from being absorbed through the intestinal wall (limiting oral bioavailability) and, more critically, prevents them from crossing the blood-brain barrier—a tightly packed layer of endothelial cells that protects the brain from large or foreign substances.
SELFTAC: Solving the Blood-Brain Barrier Challenge
Oyster Therapeutics aims to circumvent these limitations through its proprietary SELFTAC platform. Developed by founder and Chief Scientific Officer Harry Finch, a veteran medicinal chemist, the technology utilizes a "disassemble and reassemble" strategy. Rather than attempting to force a large, cumbersome molecule through biological membranes, Oyster’s degraders are engineered to split into two smaller, membrane-permeable components.
According to Oyster CEO Rob Johnson, these smaller fragments are capable of passing through the gut and the blood-brain barrier with the efficiency of traditional small molecules. Once inside the target cell—such as a diseased neuron—the components undergo a programmed chemical reaction to reassemble into the full heterobifunctional degrader. This reassembled molecule then proceeds to facilitate the degradation of pathological proteins. Johnson noted that while the underlying chemistry has been utilized in previously approved pharmaceuticals for other indications, Oyster’s application of it to the TPD space is entirely unique. This approach effectively allows the drug to act as a "Trojan Horse," entering the brain in pieces and forming the active therapeutic agent only where it is needed most.
The Strategic Focus on Pathological Tau
The company’s lead program targets tau, a protein that stabilizes microtubules in healthy neurons. In neurodegenerative diseases like Alzheimer’s, tau undergoes abnormal chemical changes, causing it to misfold and form insoluble "tangles." Unlike amyloid-beta plaques, which appear early in the disease and often plateau, the spread of tau tangles through the brain correlates closely with the actual progression of cognitive impairment and neuronal death.
Oyster’s approach is specifically designed to address "pathological" tau. This is a critical distinction in the current competitive landscape. Competitors such as Biogen and Arrowhead Pharmaceuticals are currently testing RNA-based therapies (antisense oligonucleotides and siRNA, respectively) that aim to reduce tau levels. However, these genetic medicines typically lower all forms of tau, including the healthy proteins necessary for normal brain function.
"Healthy tau is important for neuron function and it’s found in high concentrations in the brain," Johnson explained. Oyster’s technology targets an intermediary form of the protein—the stage where healthy tau begins to transition into toxic aggregates. By recognizing the specific conformational shape of this transitional tau, Oyster’s drug can selectively clear the disease-driving proteins while leaving the healthy, functional tau untouched.
Competitive Landscape and Clinical Timelines
The Alzheimer’s research field is currently energized by a mix of recent successes and ongoing challenges. In May 2026, Biogen reported preliminary Phase 2 results for its tau-targeting ASO, diranersen. While the drug showed a reduction in tau pathology and some cognitive benefits, it failed to meet its primary goal of a clear dose-response according to standard rating scales. Similarly, Arrowhead Pharmaceuticals recently released interim Phase 1/2a data for ARO-MAPT, demonstrating deep and durable tau reductions in healthy volunteers, with more data expected in 2027.
Oyster Therapeutics enters this fray with a distinct advantage: the potential for oral administration. Most current advanced Alzheimer’s treatments, including the newly approved amyloid antibodies and the experimental RNA therapies, require regular intravenous infusions or painful injections into the spinal fluid (intrathecal administration). An oral pill would not only drastically reduce manufacturing and distribution costs but also improve patient compliance and accessibility, particularly for early-stage or pre-symptomatic patients.
"What modality is going to win in that pre-symptomatic patient population?" Johnson posed. "An injectable is going to be a tough sell. If you have a safe oral solution, that’s got to be the end goal."
Chronology and Future Outlook
The journey of Oyster Therapeutics began during the global lockdowns of the Covid-19 pandemic. Harry Finch, leveraging decades of experience in drug development, dedicated that period to solving the molecular size constraints of CNS-targeted degraders. His research laid the groundwork for the SELFTAC platform, leading to the formation of the company under the name Kesmalea Therapeutics.
Following its initial funding in 2022, the company spent two years refining its chemical leads and validating the disassembly-reassembly mechanism in preclinical models. The 2026 rebrand to Oyster Therapeutics reflects a new phase of corporate maturity as the company moves toward clinical trials. The name "Oyster" serves as a metaphor for the company’s mission: the ability to transform a "grain of sand" (a pathological protein) into something valuable (a healthy brain) while acting as a natural cleanser of the biological environment.
With the $60 million in new capital, Oyster plans to transition its tau degrader into human clinical trials. While the company has not yet disclosed a specific date for its first-in-human study, the involvement of Eli Lilly suggests a rigorous path toward Phase 1 readiness. Furthermore, the company is already eyeing expansion. The SELFTAC platform is being explored for other "undruggable" neurological targets, most notably alpha-synuclein, the protein responsible for the Lewy bodies found in Parkinson’s disease.
Implications for the Biopharmaceutical Industry
The successful funding of Oyster Therapeutics underscores a broader trend in biotechnology: the "second wave" of Alzheimer’s research. After decades of focusing almost exclusively on the amyloid hypothesis, the industry is now diversifying into tau degradation, neuroinflammation, and synaptic plasticity.
Financial analysts suggest that if Oyster can successfully demonstrate that its "reassembling" degraders are safe and effective in humans, it could open the floodgates for a new class of CNS medicines. The ability to deliver large, complex therapeutic molecules across the blood-brain barrier via an oral pill would be a "holy grail" for treating not just Alzheimer’s, but also Huntington’s disease, ALS, and even certain types of brain cancer.
As the global population ages, the economic burden of neurodegenerative diseases is projected to reach trillions of dollars. In this context, Oyster’s pursuit of a cost-effective, scalable, and highly selective oral treatment represents more than just a scientific endeavor; it is a critical necessity for public health systems worldwide. For now, the industry awaits the first clinical data from the SELFTAC platform, which will determine if this innovative "cleansing" of the brain can finally turn the tide against Alzheimer’s.
